A case-control study of Fruquintinib combined with anti-PD-1 versus PD-1 in the treatment of metastatic colon cancer (a randomized, open-label phase II clinical trial)
收藏NIAID Data Ecosystem2026-03-13 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2759471
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: Fruquintinib combined with anti-PD-1 group:Fruquintinib combined with Pembrolizumab;Anti-PD-1 group:Pembrolizumab
Primary outcome(s): The level of adverse reactions in patients;Patient quality of life score
Study Design: Parallel
干预措施：呋喹替尼（Fruquintinib）联合抗PD-1（anti-PD-1）组：呋喹替尼联合帕博利珠单抗（Pembrolizumab）；抗PD-1（anti-PD-1）组：帕博利珠单抗（Pembrolizumab）
主要结局指标：患者不良反应严重程度；患者生活质量评分
研究设计：平行设计
创建时间：
2021-12-15
